

## **Pharmacological basis for abrogating myocardial reperfusion injury through a multi-target combined antioxidant therapy.**

### **Correction**

A slight change to data and code was made in the last version of the article. Instead of utilizing pharmacokinetic parameters of total N-Acetylcysteine included in “PKdata.csv” file, we utilized pharmacokinetic parameters of reduced N-Acetylcysteine obtained by Brown et al (1). Therefore, we added a second csv file named “PKdata (with reduced NAC).csv” containing the updated data. The respective changes were made to “Data and R code.pdf” in the file “Data and R code v2.pdf”.

### References:

1. Brown M, Bjorksten A, Medved I, McKenna M (2004) Pharmacokinetics of intravenous N-acetylcysteine in men at rest and during exercise. Eur J Clin Pharmacol 60:717–723.  
<https://doi.org/10.1007/s00228-004-0862-9>